90% of income is fake? Response data from listed companies. Nuohui | Nuohui Company | Listed Company
On the afternoon of the 16th, a document titled "Investigation Report on the Fraud of Nuohui Health Financial Data" circulated in the industry. An organization called Capital Watch stated in the document that the organization had spent 16 months tracking and researching various parts of China. Through various information channels, it was found that Nuohui Company created 90% of false sales revenue through continuous stocking, and the true business volume of Nuohui Company did not match the disclosed financial data.
The above document states, "Based on our good faith calculation, the actual sales revenue of Nuohui Company for the whole year of 2022 is 76.95 million yuan, which is 9 times higher than the announced 765 million yuan."
On the 16th, Nuo Hui Health opened with a sharp drop of nearly 20% in the afternoon, and has since rebounded. As of the time of publication by China News Service, it was reported at HKD 18.02 per share, down 8.90%.
Public information shows that Capital Watch was founded in 2000 and is a Wall Street financial news media.
At the recent exchange meeting on Nuohui Health held by Northeast Securities at 3pm on the 16th, Zhu Yeqing, CEO of Nuohui Health, stated that short selling agencies had contacted the company multiple times through public relations firms to seek cooperation, but were rejected by the company. Every piece of data from Nuohui Health can withstand research and argumentation.
Subsequently, Nuohui Health responded to China News Service that the company was paying attention to the report of Hong Kong short selling firm J Capital Investment. The relevant person in charge stated that J Capital Investment is the issuer of the aforementioned short selling report, and it is unclear what the relationship between J Capital Investment and Capital Watch is. The report seriously distorts the facts with the intention of damaging the reputation of the company. Nuohui Health will take legal measures to hold the company accountable and protect its legitimate rights and interests. "The information we release on the Hong Kong Stock Exchange is true and compliant. After the Hong Kong Stock Exchange closes next Monday afternoon, after the quiet period, we will hold a series of investor communication meetings and media exchange meetings to publicly and transparently communicate the company's development and performance information," said the person in charge of Nuohui Health.
According to public information, Nuohui Health was established in 2015, focusing on home early screening for high-risk cancers. It has established a pipeline consisting of four products and candidate products, focusing on early detection and cancer screening. At present, the two major home colorectal cancer screening and testing products of Nuohui Health, Changweiqing and Pupu tubes, as well as the self testing product for Helicobacter pylori, Pylori tubes, have been approved by the National Medical Products Administration.
On August 4th, Nuohui Health released a positive profit forecast for the 2023 interim report, expecting the company to record an adjusted net profit of over 45 million yuan in the first half of 2023, while the adjusted net loss for the same period in 2022 was 106.2 million yuan. This is the first time a 12 month adjusted net profit has been recorded. Turning losses into profits is mainly due to the commercialization process of the company's products and the expected cost control of marketing costs, management costs, and research and development costs.
